Pfizer says testing on its planned COVID-19 treatment pill has shown it is effective against the omicron variant while also maintaining its efficacy in reducing hospitalizations and deaths caused by other variants. According to the Associated Press, a study conducted by Pfizer on 2,250 people showed the pill reduced combined hospitalizations and deaths by about 89% among high-risk adults who took the pill shortly after noticing COVID symptoms. Testing conducted by separate labs showed the treatment remained effective against the omicron variant, despite the pill being developed before omicron was spreading around the world. The treatment was tested against a...